2008—2017年京籍宫颈癌979例分析

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (781 KB) HTML (24 KB)
输出: BibTeX | EndNote (RIS)

摘要目的分析北京市开展两癌筛查后本院2008—2017年10年间收治的京籍宫颈癌病例临床病理特点。方法收集2008年1月至2017年12月本院收治的京籍宫颈癌患者979例为研究对象。采用回顾性分析方法,从年龄、临床分期、组织病理学类型等方面分析这些京籍宫颈癌病例的特点。结果 979例京籍宫颈癌患者年龄主要集中在35~64岁,占84.8%。临床分期中早期宫颈癌(I-IIA)所占比例为56.4%,中晚期宫颈癌(IIB-IV)所占比例为43.6%。其中≤34岁组和35~64岁组以早期宫颈癌为主,所占比例分别为70.1%和57.9%;而≥65岁组则以中晚期宫颈癌居多,所占比例为76.4%。组织病理学类型以鳞癌为主,所占比例高达91.3%。结论北京市实行宫颈癌免费筛查后10年间,京籍宫颈癌患者年龄集中在免费筛查的年龄段35~64岁,因此应加强北京市宫颈癌筛查的宣传,提高人群筛查率。针对年轻和中年的宫颈癌患者确诊时多为早期,而老年妇女宫颈癌患者确诊时多为中晚期的问题,应加强老年妇女宫颈癌筛查和宫颈癌防治知识的教育。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	索红燕
	陈姝宁
	宋丹
	康琳娣
	孔为民

关键词 ：宫颈癌, 年龄, 临床分期, 组织病理学

Abstract：Objective To explore the clinicopathological characteristics of cervical cancer (CC) among local patients admitted to Beijing Obstetrics and Gynecology Hospital, during a 10-year′s period from 2008 to 2017. Methods From January 2008 to December 2017, 979 CC patients admitted to Beijing Obstetrics and Gynecology Hospital were collected. A retrospective analysis method was used to analyze the characteristics of those CC cases, including onset age, clinical stage, and histopathological type. Results The onset age among 84.8% patients was between 35 and 64 years old. According to clinical stage, the proportion of early CC (I-IIA) was 56.4%, and that of advanced CC (IIB-IV) was 43.6%. For early CC, most of them were identified among the subgroup of ≤ 34 or 35-64 years old, accounting for 70.1% and 57.9% of all analyzed early CC cases, respectively. While, for the cases of middle or late stage, most of them (i.e., 76.4%) were above 65 years old. According to the histopathological type, 91.3% was squamous cell carcinoma. Conclusion During the first 10 years of free CC screening in Beijing, the diagnosed age of cancer onset was remained between 35 and 64 years old, which suggested that the CC screening in Beijing should be strengthened to increase the rate of population coverage. For young- or middle-aged patients, most CC cases were diagnosed at their early stage; for elderly women, the diagnoses were mostly possible at their middle and late stages. The comparison suggests that the education of screening, prevention, treatment for CC should be strengthened among elderly women.

Key words： cervical cancer age clinical stage histopathology

收稿日期: 2020-06-08

通讯作者: 孔为民(kwm1967@ccmu.edu.cn)

引用本文:

索红燕, 陈姝宁, 宋丹, 康琳娣, 孔为民. 2008—2017年京籍宫颈癌979例分析[J]. 中国生育健康杂志, 2021, 32(3): 229-232. SUO Hongyan, CHEN Shuning, SONG Dan, KANG Lindi, KONG Weimin. Analysis of 979 cervical cancer patients in Beijing from 2008 to 2017. Chinese Journal of Reproductive Health, 2021, 32(3): 229-232.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2021/V32/I3/229

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin,2018,68:394-424.
2 Wild CP,Weiderpass E,Stewart B W.World cancer report:cancer research for cancer prevention.2020:394.https://publications.iarc.fr/Non-Series-Publications.
3 韩历丽,齐庆青,王朝,等.北京市宫颈癌和乳腺癌筛查现况与结果分析.中华健康管理学杂志,2011,05:292-294.
4 陶霞,温宏武,李雪迎,等.宫颈癌住院患者10年临床特点变化及筛查作用探讨.实用妇产科杂志,2016,32:106-109.
5 章静菲,王彤,武明辉,等.北京市1399例宫颈癌的流行现状及临床特点.中华医学杂志,2011,91:3058-3061.
6 王卉,王文豪.miR-375在宫颈癌中的研究进展.国际妇产科学杂志,2020,47:138-142.
7 卓娜,柏璐,张晓红,等.早期宫颈癌保留生育功能的研究进展.现代肿瘤医学,2019,27:4125-4128.
8 王延洲,梁志清.宫颈癌保留生育功能手术方案优化.中国临床医生杂志,2020,48:262-265.
9 Saslow D,Solomon D,Lawson HW,et al.American Cancer Society,American Society for Colposcopy and Cervical Pathology,and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.Am J Clin Pathol,2012,137:516-542.
10 孙建衡,盛修贵,白萍.妇科肿瘤学.第2版.北京:北京大学医学出版社,2019:536.
11 黄艮平.宫颈腺癌的病因学研究进展.国际妇产科学杂志,2019,46:104-108.
12 Eduardo MG,Campaner AB,Silva MA,et al.Apoptosis Phenomena in squamous cell carcinomas and adenocarcinomas of the uterine cervix.Pathol Oncol Res,2015,21,887-892.
13 Kurman RJ,Carcangiu ML,Herrington CS,et al.WHO classification of tumors of female reproductive organs.Fourth edition.Lyon:International Agency for research on cancer,2014:176-178.